Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on May 27, 2026, Actinium Pharmaceuticals, Inc. (the “Company”) received notice from NYSE American LLC (“NYSE American”) that the Company was not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide (the “Company Guide”). The Company submitted a compliance plan to NYSE American on June 18, 202…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 27, 2026, Actinium Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million…

CFO — Steve O’Loughlin: Steve O’Loughlin resigned as CFO to pursue other opportunities.

Director — Ajit S. Shetty, June S. Almenoff: Routine annual board election of directors.

Changes in Registrant's Certifying Accountant. (a) Resignation of Independent Registered Public Accounting Firm Based on information provided by Marcum LLP (“ Marcum ”), on November 1, 2024, CBIZ CPAs P.C. (“ CBIZ CPAs ”) acquired the attest business of Marcum. On May 08, 2025, Actinium Pharmaceuticals, Inc. (the “ Company ”) dismissed Marcum as the Company’s independent registered public accounting firm as a result of such acquisition. The audit report of Marcum on the Company’s consolidated…

Director — Sandesh Seth, Jeffrey W. Chell: Routine re-election of directors at the annual meeting.

Director — June Almenoff, M.D., Ph.D.: Dr. June Almenoff was appointed as a director and received stock options.

Director — David Nicholson, Richard I. Steinhart: Routine annual board election of directors.

Class III director — Ajit S. Shetty: Annual re-election of a director.

Entry into a Material Definitive Agreement. As previously disclosed in a Registration Statement on Form S-3 filed with the Securities and Exchange Commission (the “ SEC ”) on August 7, 2020, Actinium Pharmaceuticals, Inc. (the “ Company ”) entered into a Capital on Demand™ Sales Agreement (the “ Original Sales Agreement ”) with JonesTrading Institutional Services LLC (“ JonesTrading ”), dated August 7, 2020, relating to the sale of shares of the Company’s common stock, par value $0.001 per sh…

Entry into a Material Definitive Agreement. On April 7, 2022, Actinium Pharmaceuticals, Inc. (the “ Company ”) entered into a license and supply agreement (the “ License Agreement ”) with Immedica Pharma AB (“ Immedica ”), pursuant to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab) in the European Economic Area, Middle East and North Africa (EUMENA) including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Kuwait,…

Director — Sandesh Seth and Jeffrey W. Chell: Election of two Class II directors at the annual meeting.

Chief Medical Officer — Dr. Mark S. Berger: Dr. Mark S. Berger resigned as Chief Medical Officer.

Director: Election of two Class I directors at the annual meeting.